{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:12:59Z","timestamp":1771009979861,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1093\/ndt\/gfr753","type":"journal-article","created":{"date-parts":[[2012,1,14]],"date-time":"2012-01-14T15:35:04Z","timestamp":1326555304000},"page":"2866-2872","source":"Crossref","is-referenced-by-count":34,"title":["Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease"],"prefix":"10.1093","volume":"27","author":[{"given":"Ferenc","family":"Sztanek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildik\u00f3","family":"Seres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariann","family":"Harangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"L\u0151csey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Padra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy J.R.","family":"Paragh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Asztalos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"Paragh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"key":"key\n\t\t\t\t20170518085116_GFR753C1","doi-asserted-by":"crossref","first-page":"V67","DOI":"10.1093\/ndt\/gfh1059","article-title":"Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease","volume":"19","author":"Zoccali","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170518085116_GFR753C2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1291\/hypres.28.181","article-title":"Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension","volume":"28","author":"Okubo","year":"2005","journal-title":"Hypertens Res"},{"key":"key\n\t\t\t\t20170518085116_GFR753C3","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0891-5849(02)01429-6","article-title":"Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice","volume":"34","author":"Rozenberg","year":"2003","journal-title":"Free Radic Biol Med"},{"key":"key\n\t\t\t\t20170518085116_GFR753C4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0021-9150(03)00236-3","article-title":"Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia","volume":"170","author":"Beltowski","year":"2003","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20170518085116_GFR753C5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1515\/CCLM.2002.116","article-title":"The paraoxonase-1 codon 192 polymorphism is associated with fasting total cholesterol and LDL-cholesterol concentrations only in postmenopausal women. The REGICOR study","volume":"40","author":"Senti","year":"2002","journal-title":"Clin Chem Lab Med"},{"key":"key\n\t\t\t\t20170518085116_GFR753C6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1096\/fj.09-144410","article-title":"Paraoxonase 1 protects against protein N-homocysteinylation in humans","volume":"24","author":"Perla-Kaj\u00e1n","year":"2010","journal-title":"FASEB J"},{"key":"key\n\t\t\t\t20170518085116_GFR753C7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-60761-350-3_11","article-title":"The role of paraoxonase 1 in the detoxification of homocysteine thiolactone","volume":"660","author":"Jakubowski","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"key\n\t\t\t\t20170518085116_GFR753C8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1515\/CCLM.2011.004","article-title":"Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis","volume":"49","author":"Gugliucci","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"key\n\t\t\t\t20170518085116_GFR753C9","first-page":"4","article-title":"The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status","volume":"52","author":"Domaga\u0142a","year":"2006","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"key\n\t\t\t\t20170518085116_GFR753C10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.metabol.2006.06.001","article-title":"Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus","volume":"55","author":"Lakshman","year":"2006","journal-title":"Metabolism"},{"key":"key\n\t\t\t\t20170518085116_GFR753C11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cccn.2005.03.046","article-title":"Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay","volume":"359","author":"Kosaka","year":"2005","journal-title":"Clin Chim Acta"},{"key":"key\n\t\t\t\t20170518085116_GFR753C12","first-page":"885","article-title":"Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans","volume":"50","author":"Lacinski","year":"2004","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"key\n\t\t\t\t20170518085116_GFR753C13","doi-asserted-by":"crossref","first-page":"c114","DOI":"10.1159\/000092020","article-title":"Hyperleptinemia is not responsible for decreased paraoxonase activity in hemodialysis patients","volume":"103","author":"Varga","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"key\n\t\t\t\t20170518085116_GFR753C14","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1681\/ASN.2005121379","article-title":"Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease","volume":"17","author":"Matsuguma","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518085116_GFR753C15","first-page":"159","article-title":"Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy","volume":"58","author":"Be\u0142towski","year":"2006","journal-title":"Pharmacol Rep"},{"key":"key\n\t\t\t\t20170518085116_GFR753C16","doi-asserted-by":"crossref","first-page":"c180","DOI":"10.1159\/000104429","article-title":"Improvement in central arterial pressure waveform during hemodialysis is related to a reduction in asymmetric dimethylarginine (ADMA) levels","volume":"106","author":"Soveri","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"key\n\t\t\t\t20170518085116_GFR753C17","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1097\/01.tp.0000183750.22675.be","article-title":"Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation","volume":"80","author":"Yilmaz","year":"2005","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20170518085116_GFR753C18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000045489","article-title":"Serum paraoxonase activity changes in uremic and kidney-transplanted patients","volume":"83","author":"Paragh","year":"1999","journal-title":"Nephron"},{"key":"key\n\t\t\t\t20170518085116_GFR753C19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0090-9556(25)07065-5","article-title":"Purification of human serum paraoxonase\/arylesterase. Evidence for one esterase catalyzing both activities","volume":"19","author":"Gan","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20170518085116_GFR753C20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem Pharmacol"},{"key":"key\n\t\t\t\t20170518085116_GFR753C21","first-page":"231","article-title":"Rapid genotyping of paraoxonase 55 and 192 mutations by melting point analysis using real time PCR technology","volume":"33","author":"Pocsai","year":"2003","journal-title":"Clin Chim Acta"},{"key":"key\n\t\t\t\t20170518085116_GFR753C22","doi-asserted-by":"crossref","first-page":"c46","DOI":"10.1159\/000228075","article-title":"Discordance in human paraoxonase-1 gene between phenotypes and genotypes in chronic kidney disease","volume":"113","author":"Paragh","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"key\n\t\t\t\t20170518085116_GFR753C23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0022-510X(01)00439-7","article-title":"Paraoxonase 1 Met\u2014Leu 54 polymorphism is associated with Parkinson's disease","volume":"184","author":"Akhmedova","year":"2001","journal-title":"J Neurol Sci"},{"key":"key\n\t\t\t\t20170518085116_GFR753C24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/hdy.2008.110","article-title":"Determinants of variation in human serum paraoxonase activity","volume":"102","author":"Rainwater","year":"2009","journal-title":"Heredity"},{"key":"key\n\t\t\t\t20170518085116_GFR753C25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1194\/jlr.M400511-JLR200","article-title":"Human paraoxonases (PON1, PON2 and PON3) are lactonases with overlaping and distinct substrate specificities","volume":"46","author":"Draganov","year":"2005","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20170518085116_GFR753C26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000045161","article-title":"The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia","volume":"80","author":"Paragh","year":"1998","journal-title":"Nephron"},{"key":"key\n\t\t\t\t20170518085116_GFR753C27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/08860220701810315","article-title":"Serum cystatin C as an endogenous marker of renal function in patients with chronic kidney disease","volume":"30","author":"Hojs","year":"2008","journal-title":"Ren Fail"},{"key":"key\n\t\t\t\t20170518085116_GFR753C28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(96)05953-9","article-title":"The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications","volume":"127","author":"B\u00f6ger","year":"1996","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20170518085116_GFR753C29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ncpneph0143","article-title":"Arginine, arginine analogs and nitric oxide production in chronic kidney disease","volume":"2","author":"Baylis","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"key\n\t\t\t\t20170518085116_GFR753C30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1567-5688(03)00033-3","article-title":"ADMA and oxidative stress","volume":"4","author":"Sydow","year":"2003","journal-title":"Atheroscler Suppl"},{"key":"key\n\t\t\t\t20170518085116_GFR753C31","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(01)07217-8","article-title":"Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study","volume":"358","author":"Zoccali","year":"2001","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170518085116_GFR753C32","first-page":"77","article-title":"Hyperhomocysteinaemia and end stage renal disease","volume":"10","author":"Gupta","year":"1997","journal-title":"J Nephrol"},{"key":"key\n\t\t\t\t20170518085116_GFR753C33","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.clinbiochem.2006.05.010","article-title":"Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease","volume":"39","author":"Kerkeni","year":"2006","journal-title":"Clin Biochem"},{"key":"key\n\t\t\t\t20170518085116_GFR753C34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1155\/2009\/819862","article-title":"Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients","volume":"26","author":"Varga","year":"2009","journal-title":"Dis Markers"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/27\/7\/2866\/12842622\/gfr753.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:04:22Z","timestamp":1742328262000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article-lookup\/doi\/10.1093\/ndt\/gfr753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,12]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,1,12]]},"published-print":{"date-parts":[[2012,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfr753","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1,12]]}}}